Publications by authors named "Brannon Flores"
Article Synopsis
- Treatment with venetoclax combined with hypomethylating agents (HMAs) is a standard option for elderly or fragile patients newly diagnosed with acute myeloid leukemia (AML).
- A study analyzed data from 169 patients undergoing this treatment in the U.S., finding that the median age at diagnosis was 77 and many were treated in community settings.
- Results showed a median treatment duration of 5.2 months and an overall survival rate of 8.6 months, highlighting that managing venetoclax dosing and schedule can improve patient outcomes.
